Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC

Launched by SHU WANG · Nov 20, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating two different ways of administering a medication called capecitabine for patients with early-stage triple negative breast cancer who still have tumor cells present after their initial treatment. Researchers want to find out if giving a full dose of capecitabine for 6 to 8 cycles is more effective and safe compared to a lower, continuous dose of capecitabine given over one year. The goal is to see which method helps improve survival rates for patients who did not achieve a complete response to their previous treatments.

To participate, individuals must be diagnosed with triple negative breast cancer, have specific tumor characteristics, and show evidence of remaining invasive cancer after their initial treatment. Participants can expect to receive either the standard or metronomic (lower dose) capecitabine treatment, and they will be closely monitored for safety and effectiveness throughout the trial. Importantly, this study is currently recruiting participants, and it allows for those who have received immunotherapy during their earlier treatment stages.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Patients with triple negative breast cancer diagnosed by biopsy in Peking University People's Hospital;
• • 2) The clinical stages before treatment were T1-T4, N0-N3, M0;
• • 3) Received treatment and operation in our hospital, and had hospitalization records;
• • 4) Neoadjuvant chemotherapy is unlimited, and immunotherapy is allowed in neoadjuvant and/or adjuvant treatment;
• • 5) Postoperative pathology confirmed the presence of residual invasive breast cancer in the breast and/or axillary lymph nodes;
• • 6) Has signed and agreed to participate in the PKUPH breast disease cohort study.
• Exclusion Criteria:
• • 1) Lack of clinical and pathological data (such as imaging data and pathological data);
• • 2) Patients with metastatic breast cancer or bilateral breast cancer;
• • 3) Failure to perform radical surgery;
• • 4) BRCA has pathogenic or possibly pathogenic mutations, and received intensive treatment with PARP inhibitors after operation